Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. (ANGN) priced its initial public offering on Feb 5, 2021 at $16.00 per share, within its $14.00–$16.00 range, raising $80M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $459.5M. Latham & Watkins advised the company and Cooley advised the underwriters.

At its 2021 IPO, Angion Biomedica Corp. (now Elicio Therapeutics) was a late-stage biopharmaceutical company developing small molecule therapeutics for acute organ injuries and fibrotic diseases. Its lead candidate, ANG-3777, was licensed to Vifor Pharma for renal indications such as delayed graft function and cardiac surgery-associated acute kidney injury.

Status

IPO

Ticker

ANGN

Exchange

Nasdaq Global Select

Priced

Feb 5, 2021

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$80M

Market cap at IPO price

$459.5M

First filed

Apr 14, 2014

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.